Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 9/20 | 0.75 |
| ▸ | NFKB2 | Q00653 | 9/20 | 0.75 |
| ▸ | RELA | Q04206 | 9/20 | 0.75 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22227389 | 1.00 | NFKB1 (0.75) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL6917362 | 1.00 | NFKB1 (0.75) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL14586683 | 0.86 | NFKB1 (1.00) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL14586681 | 0.86 | NFKB1 (1.00) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL5600252 | 0.86 | NFKB1 (1.00) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL1719310 | 0.78 | NFKB1 (0.53) | NFKB1NFKB2RELADRD2KDM1A | |
| SCHEMBL13836558 | 0.75 | NFKB1 (0.44) | NFKB1NFKB2RELA | |
| SCHEMBL10423458 | 0.75 | NFKB1 (0.64) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL22241778 | 0.74 | NFKB1 (0.55) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL2630503 | 0.74 | NFKB1 (0.55) | NFKB1NFKB2RELABTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023091438-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | NFKB1 1604/4885NFKB2 2316/4885RELA 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.